Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dual inhibition of JAK1/2 kinases and BCL2: a promising therapeutic strategy for acute myeloid leukemia.

Leukemia - 1 Sept 2018

Kurtz Stephen E, Eide Christopher A, Kaempf Andy, Mori Motomi, Tognon Cristina E, Borate Uma, Druker Brian J, Tyner Jeffrey W

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Drug Evaluation, Preclinical
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Janus Kinase 1

Share to Janus Kinase 2

Share to Leukemia, Myeloid, Acute

Share to Molecular Targeted Therapy

Share to Proto-Oncogene Proteins c-bcl-2

Source

Open in PubMed Open full text

Identifiers

PMID: 30082821
DOI: 10.1038/s41375-018-0225-7
PMCID: PMC6168939

Genes

BCL2
JAK1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dual inhibition of JAK1/2 kinases and BCL2: a promising therapeutic strategy for acute myeloid leukemia.PMID 30082821Read ↗

Targeting the Akt, GSK-3, Bcl-2 axis in acute myeloid leukemiaSemantic proximity Read ↗

Dual inhibition of Jak2 and STAT5 enhances killing of myeloproliferative neoplasia cellsSemantic proximity Read ↗

Combined Targeting of JAK2 and Bcl-2/Bcl-xL to Cure Mutant JAK2-Driven Malignancies and Overcome Acquired Resistance to JAK2 InhibitorsSemantic proximity Read ↗

Mcl-1 as a therapeutic target in acute myelogenous leukemia (AML)Semantic proximity Read ↗

BCL2 and MCL1 inhibitors for hematologic malignanciesSemantic proximity Read ↗

Targeting Bcl-2 Proteins in Acute Myeloid LeukemiaSemantic proximity Read ↗

Allosteric SHP2 Inhibition Increases Apoptotic Dependency on BCL2 and Synergizes with Venetoclax in <i>FLT3-</i> and <i>KIT-</i> Mutant AMLSemantic proximity Read ↗

Jak2 inhibitors: rationale and role as therapeutic agents in hematologic malignancies.Semantic proximity Read ↗

Janus Kinase-Signal Transducer and Activator of Transcription Inhibitors for the Treatment and Management of CancerSemantic proximity Read ↗

A Pan-BCL2 Inhibitor Renders Bone-Marrow-Resident Human Leukemia Stem Cells Sensitive to Tyrosine Kinase InhibitionSemantic proximity Read ↗

CK2 inhibitor, CX-4945, enhances BH3 priming and promotes apoptosis of venetoclax-resistant AML by targeting antiapoptotic proteinsSemantic proximity Read ↗

The rise of apoptosis: targeting apoptosis in hematologic malignanciesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.